NCT00547365View on ClinicalTrials.gov

Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart Dysfunction

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
Multiple MyelomaPlasma Cell Neoplasm
Interventions
BIOLOGICAL

Human immune globulin intravenous (IGIV)

Analyze the therapeutic potential of human immune globulin intravenous (IGIV) when given to patients with cardiac-associated AL amyloidosis

Trial Locations (2)

37849

St. Mary's Medical Center, Powell

37901

Baptist Regional Cancer Center at Baptist Riverside, Knoxville

All Listed Sponsors
lead

University of Tennessee

OTHER

NCT00547365 - Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart Dysfunction | Biotech Hunter | Biotech Hunter